It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
TAB182 (also named TNKS1BP1), a binding protein of tankyrase 1, has been found to participate in DNA repair. Our previous study has revealed the involvement of TAB182 in the radioresistance of esophageal squamous cell carcinoma (ESCC) cells. However, whether TAB182 contributes to the ESCC tumorigenesis and progression remains unclear. In this study, we found that highly expressed TAB182 is closely associated with a poor prognosis of patients with ESCC. TAB182 silencing reduced ESCC cell proliferation and invasion in vitro, tumorigenicity and metastasis in vivo. RNA-seq and IP-MS analysis revealed that TAB182 could affect the β-catenin signaling pathway via interacting with β-catenin. Furthermore, TAB182 prevented β-catenin to be phosphorylated by GSK3β and recruited four and a half of LIM-only protein 2 (FHL2), which thereby promoted β-catenin nucleus translocation to result in activation of the downstream targets transcription in ESCC cells. Our findings demonstrate that TAB182 enhances tumorigenesis of esophageal cancer by promoting the activation of the β-catenin signaling pathway, which provides new insights into the molecular mechanisms by which TAB182 accelerates progression of ESCC.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Cancer Center Core Laboratory, Suzhou, P.R. China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984)
2 The Affiliated Suqian Hospital of Xuzhou Medical University and Nanjing Drum Tower Hospital Group Suqian Hospital, Suqian, P.R. China (GRID:grid.428392.6) (ISNI:0000 0004 1800 1685)
3 Medical College of Soochow University, School of Radiation Medicine and Protection, Suzhou, China (GRID:grid.263761.7) (ISNI:0000 0001 0198 0694)
4 University of Oklahoma Health Science Center, Department of Pathology, Oklahoma City, USA (GRID:grid.266902.9) (ISNI:0000 0001 2179 3618)
5 First Affiliated Hospital of Nanjing Medical University, Department of Thoracic Surgery, Nanjing, China (GRID:grid.412676.0) (ISNI:0000 0004 1799 0784)
6 The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Suzhou Cancer Center Core Laboratory, Suzhou, China (GRID:grid.440227.7) (ISNI:0000 0004 1758 3572)